These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10498468)

  • 21. Superior efficacy of oral ganciclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients.
    Somerville T; Hurst G; Alloway R; Gaber A; Shokouh-Amiri MH; Stratta R
    Transplant Proc; 1998 Jun; 30(4):1546-8. PubMed ID: 9636628
    [No Abstract]   [Full Text] [Related]  

  • 22. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valaciclovir update.
    Bell AR
    Adv Exp Med Biol; 1999; 458():149-57. PubMed ID: 10549387
    [No Abstract]   [Full Text] [Related]  

  • 24. Ganciclovir studies leave clinicians confused.
    AIDS Alert; 1995 Nov; 10(11):139-41. PubMed ID: 11362926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines.
    Kalil AC; Florescu DF
    Transplantation; 2011 Jan; 91(1):e8-9; author reply e10. PubMed ID: 21441850
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.
    Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M
    BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
    Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
    Falagas ME; Vardakas KZ
    Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acyclovir to prevent cytomegalovirus infection after renal transplantation.
    Wong T; Toupance O; Chanard J
    Ann Intern Med; 1991 Jul; 115(1):68. PubMed ID: 1646586
    [No Abstract]   [Full Text] [Related]  

  • 31. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
    Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
    Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
    Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
    Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir.
    Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P
    Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytomegalovirus infection and prophylaxis in renal transplantation: financial considerations.
    Wright FH; Banowsky LH
    Transplant Proc; 1998 Jun; 30(4):1318-9. PubMed ID: 9636535
    [No Abstract]   [Full Text] [Related]  

  • 35. [Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients].
    Moreno J; Montero JL; Gavilán F; Costán G; Herrero C; Cárdenas M; Sánchez-Guijo P; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 1999 Oct; 17(8):382-5. PubMed ID: 10563084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acyclovir to prevent cytomegalovirus infection in renal-graft recipients.
    Grundy JE; Griffiths PD
    N Engl J Med; 1989 Nov; 321(18):1268-9. PubMed ID: 2552315
    [No Abstract]   [Full Text] [Related]  

  • 37. Ganciclovir-resistant cytomegalovirus.
    Legendre C
    Lancet; 2000 Oct; 356(9238):1356. PubMed ID: 11073050
    [No Abstract]   [Full Text] [Related]  

  • 38. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
    Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
    N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.
    Hodson EM; Jones CA; Webster AC; Strippoli GF; Barclay PG; Kable K; Vimalachandra D; Craig JC
    Lancet; 2005 Jun 18-24; 365(9477):2105-15. PubMed ID: 15964447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of cytomegalovirus disease in renal allograft recipients.
    Balfour HH
    Scand J Infect Dis Suppl; 1991; 80():88-93. PubMed ID: 1725064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.